Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biosimilar Guidances Could Be Left Out In Cold By White House Regulatory Freeze

Jan 26 2017

• By Sue Sutter

Related Content

Industry Communications With Payors: US FDA Okays Info On Investigational Drugs

Jan 19 2017

Biologic Product Naming: US FDA Sticks With Suffixes ‘Devoid Of Meaning’

Jan 13 2017

FDA New Year’s Resolution: Guidances On Payor Communications, Biosimilarity

Jan 14 2017

Biosimilars: Postmarketing Data Alone Not Enough For Interchangeability

Jan 18 2017

Off-Label Communication: When Does It Align With Approved Labeling?

Jan 18 2017

Zika Vaccine Makers, 21st Century Cures Task Force Hit By Regulatory Freeze

Jan 26 2017

FDA's Document Dump: Guidance Release Skyrockets Ahead Of Trump's Arrival

Jan 22 2017

Additional Topics

United States Regulation Biosimilars Advertising, Marketing & Sales BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window